Bayer AG – Product Pipeline Review

Global Markets Direct’s, ‘Bayer AG – Product Pipeline Review – 2016’, provides an overview of the Bayer AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bayer AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Bayer AG

The report provides overview of Bayer AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Bayer AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Bayer AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bayer AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bayer AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Bayer AG Snapshot 7

Bayer AG Overview 7

Key Information 7

Key Facts 7

Bayer AG - Research and Development Overview 8

Key Therapeutic Areas 8

Bayer AG - Pipeline Review 15

Pipeline Products by Stage of Development 15

Pipeline Products - Monotherapy 16

Pipeline Products - Combination Treatment Modalities 17

Pipeline Products - Partnered Products 18

Pipeline Products - Out-Licensed Products 20

Bayer AG - Pipeline Products Glance 22

Bayer AG - Late Stage Pipeline Products 22

Bayer AG - Clinical Stage Pipeline Products 25

Bayer AG - Early Stage Pipeline Products 30

Bayer AG - Unknown Stage Pipeline Products 33

Bayer AG - Drug Profiles 34

aflibercept 34

dienogest 37

Kovaltry 38

(candesartan cilexetil + nifedipine) 40

amikacin sulfate 41

ciprofloxacin hydrochloride 43

copanlisib hydrochloride 45

damoctocog alfa pegol 49

finerenone 50

nifurtimox 51

radium Ra 223 dichloride 52

regorafenib 55

rivaroxaban 59

tedizolid phosphate 65

(anastrozole + levonorgestrel) 68

anetumab ravtansine 69

BAY-1067197 71

BAY-1142524 72

molidustat 73

refametinib 75

riociguat 78

roniciclib 80

vericiguat 82

vilaprisan 83

sorafenib tosylate 84

BAY sGCstim 89

BAY-1082439 90

BAY-1093884 91

BAY-1112054 92

BAY-1125976 93

BAY-1128688 94

BAY-1129980 95

BAY-1143269 96

BAY-1143572 97

BAY-1161909 98

BAY-1163877 99

BAY-1179470 100

BAY-1187982 101

BAY-1213790 102

BAY-1214784 103

BAY-1217389 104

BAY-1251152 105

BAY-1862864 106

Drug for Diabetic Foot Ulcer 107

Monoclonal Antibodies for Oncology 108

Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers 109

Monoclonal Antibody for Undisclosed Indication 110

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis 111

Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders 112

Small Molecule to Inhibit Kinase for Inflammation and Oncology 113

BAY sGCact 114

BAY-1001931 115

BAY-1024767 116

BAY-1436032 117

BAY-606583 118

Bay-846 119

Immunotherapy for Oncology 120

Monoclonal Antibodies for Undisclosed Indication 121

Monoclonal Antibody to Inhibit CGEN-15001T for Oncology 122

Monoclonal Antibody to Inhibit CGEN-15022 for Oncology 123

Monocloncal Antibody Conjugate to Inhibit PDGFR-Beta Receptor for Solid Tumors 125

Recombinant Protein To Inhibit HER-2 Receptor for Breast Cancer 126

Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder 127

Small Molecules to Inhibit Mitogen Activated Protein Kinase Kinase for Oncology 128

Small Molecules to Inhibit MTH1 for Oncology 129

Small Molecules to Inhibit Wnt Pathway for Oncology 130

SMYD-2BAY02 131

ZK-191784 132

ZK-216348 134

Drugs for Endometriosis and Uterine Fibroids 135

Recombinant Protein for Solid Tumors 136

Small Molecule to Inhibit Epigenetic Target for Oncology 137

Small Molecules for Cardiovascular Disease 138

Small Molecules for Oncology 139

Small Molecules to Inhibit GLUT1 and GLUT2 140

Small Molecule for Undisclosed Indication 141

Bayer AG - Pipeline Analysis 142

Bayer AG - Pipeline Products by Target 142

Bayer AG - Pipeline Products by Route of Administration 147

Bayer AG - Pipeline Products by Molecule Type 148

Bayer AG - Pipeline Products by Mechanism of Action 149

Bayer AG - Recent Pipeline Updates 153

Bayer AG - Dormant Projects 227

Bayer AG - Discontinued Pipeline Products 230

Discontinued Pipeline Product Profiles 230

Bayer AG - Locations And Subsidiaries 232

Head Office 232

Other Locations & Subsidiaries 232

Appendix 243

Methodology 243

Coverage 243

Secondary Research 243

Primary Research 243

Expert Panel Validation 243

Contact Us 243

Disclaimer 244

List of Tables

List of Tables

Bayer AG, Key Information 13

Bayer AG, Key Facts 13

Bayer AG – Pipeline by Indication, 2016 15

Bayer AG – Pipeline by Stage of Development, 2016 21

Bayer AG – Monotherapy Products in Pipeline, 2016 22

Bayer AG – Combination Treatment Modalities in Pipeline, 2016 23

Bayer AG – Partnered Products in Pipeline, 2016 24

Bayer AG – Partnered Products/ Combination Treatment Modalities, 2016 25

Bayer AG – Out-Licensed Products in Pipeline, 2016 26

Bayer AG – Out-Licensed Products/ Combination Treatment Modalities, 2016 27

Bayer AG – Pre-Registration, 2016 28

Bayer AG – Phase III, 2016 29

Bayer AG – Phase II, 2016 31

Bayer AG – Phase I, 2016 33

Bayer AG – Preclinical, 2016 36

Bayer AG – Discovery, 2016 38

Bayer AG – Unknown, 2016 39

Bayer AG – Pipeline by Target, 2016 148

Bayer AG – Pipeline by Route of Administration, 2016 153

Bayer AG – Pipeline by Molecule Type, 2016 154

Bayer AG – Pipeline Products by Mechanism of Action, 2016 155

Bayer AG – Recent Pipeline Updates, 2016 159

Bayer AG – Dormant Developmental Projects,2016 233

Bayer AG – Discontinued Pipeline Products, 2016 236

Bayer AG, Subsidiaries 238

List of Figures

List of Figures

Bayer AG – Pipeline by Top 10 Indication, 2016 15

Bayer AG – Pipeline by Stage of Development, 2016 21

Bayer AG – Monotherapy Products in Pipeline, 2016 22

Bayer AG – Combination Treatment Modalities in Pipeline, 2016 23

Bayer AG – Partnered Products in Pipeline, 2016 24

Bayer AG – Out-Licensed Products in Pipeline, 2016 26

Bayer AG – Pipeline by Top 10 Target, 2016 148

Bayer AG – Pipeline by Top 10 Route of Administration, 2016 153

Bayer AG – Pipeline by Top 10 Molecule Type, 2016 154

Bayer AG – Pipeline Products by Top 10 Mechanism of Action, 2016 155

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports